# GLP-1 Drugs May Improve Fertility in Both Men and Women
GLP-1 receptor agonists like semaglutide and tirzepatide, widely prescribed for weight loss and diabetes, now show promise for fertility outcomes in both sexes, according to emerging research.
The connection centers on weight and metabolic health. Obesity impairs fertility through multiple mechanisms: excess fat tissue disrupts hormone balance, increases inflammation, and damages sperm quality in men while interfering with ovulation and egg quality in women. Since GLP-1s produce substantial weight loss by regulating appetite, they address a root cause affecting reproductive function.
Recent data reveals specific improvements. In women, weight loss from GLP-1 use correlates with restored menstrual cycles, better ovulation patterns, and improved egg quality. Men show enhanced sperm motility and concentration following treatment-related weight loss. One study found that participants losing 10-15 percent of body weight on GLP-1s experienced measurable improvements in reproductive hormone levels within months.
The mechanism works through multiple pathways. GLP-1s reduce insulin resistance, which plays a central role in conditions like polycystic ovary syndrome (PCOS), a leading cause of female infertility. They also lower inflammation markers that damage reproductive tissues and suppress anti-Müllerian hormone (AMH), a key indicator of ovarian reserve.
Fertility specialists increasingly recognize these secondary benefits. Dr. Jason James, an reproductive endocrinologist, notes that weight loss remains one of the most effective non-pharmacological interventions for fertility, and GLP-1s deliver results many patients struggle to achieve through diet alone.
However, researchers caution that GLP-1s require careful timing around conception. These medications may need discontinuation during pregnancy since long-term safety data remains limited. Women planning conception should discuss timing